GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will host a webcast and conference call at […]

(NASDAQ:ACRS), – Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class – – Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials – – Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition

(NasdaqGM:LRMR), BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so

(NasdaqGM:BBNX), IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results

Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance GlobeNewswire July 29, 2025 IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and

Larimar Therapeutics Announces Proposed Underwritten Public Offering GlobeNewswire July 29, 2025 BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and,

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints GlobeNewswire July 29, 2025 – Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class –

Red Rock Resorts, Inc. (“Red Rock Resorts,” “we” or the “Company”) (NASDAQ: RRR) today reported financial results for the second quarter ended June 30, 2025. Second Quarter Results Consolidated Operations — Net revenues were $526.3 million for the second quarter of 2025, an increase of 8.2%, or $39.9 million, from $486.4 million in the same

(NASDAQ:CAR), PARSIPPANY, N.J., July 29, 2025 (GLOBE NEWSWIRE) — Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2025 today. We ended the quarter with revenues of $3.0 billion, net income of $5 million, and Adjusted EBITDA1 of $277 million. STRATEGIC ANNOUNCEMENTS Launch of Avis First – On July 21st, we launched

(NASDAQ:DFLI),(NASDAQ:DFLIW), RENO, Nev., July 29, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to investors who so